MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Corcept Therapeutics Inc

Deschisă

SectorSănătate

70.65 -2.3

Rezumat

Modificarea prețului

24h

Curent

Minim

69.37

Maxim

75.97

Indicatori cheie

By Trading Economics

Venit

-16M

31M

Vânzări

-656K

182M

P/E

Medie Sector

51.138

57.333

EPS

0.26

Marjă de profit

16.904

Angajați

500

EBITDA

-21M

26M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+87.35% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-375M

6.6B

Deschiderea anterioară

72.95

Închiderea anterioară

70.65

Corcept Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr. 2025, 23:37 UTC

Top știri

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr. 2025, 23:36 UTC

Top știri

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr. 2025, 23:13 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr. 2025, 23:09 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr. 2025, 22:51 UTC

Top știri
Achiziții, Fuziuni, Preluări

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr. 2025, 22:48 UTC

Top știri

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr. 2025, 22:38 UTC

Market Talk
Câștiguri

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr. 2025, 22:24 UTC

Market Talk
Câștiguri

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr. 2025, 22:23 UTC

Câștiguri

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr. 2025, 22:09 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr. 2025, 22:00 UTC

Market Talk
Câștiguri

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr. 2025, 21:39 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr. 2025, 21:23 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr. 2025, 21:04 UTC

Câștiguri

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr. 2025, 21:02 UTC

Câștiguri

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparație

Modificare preț

Corcept Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

87.35% sus

Prognoză pe 12 luni

Medie 134.5 USD  87.35%

Maxim 150 USD

Minim 115 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorcept Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.